基于蛋白组学和代谢组学研究射血分数保留型心力衰竭不同证候的生物学特征临床试验研究方案

注册号:

Registration number:

ITMCTR2024000120

最近更新日期:

Date of Last Refreshed on:

2024-07-07

注册时间:

Date of Registration:

2024-07-07

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

基于蛋白组学和代谢组学研究射血分数保留型心力衰竭不同证候的生物学特征临床试验研究方案

Public title:

Clinical Trial Protocol for Investigating Biological Characteristics of Different Syndromes in Heart Failure with Preserved Ejection Fraction (HFpEF) Based on Proteomics and Metabolomics Studies

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于蛋白组学和代谢组学研究射血分数保留型心力衰竭不同证候的生物学特征

Scientific title:

Proteomics and metabolomics-based study of the biological characteristics of different TCM syndromes of heart failure with preserved ejection fraction (HFpEF)

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张啸

研究负责人:

刘剑刚

Applicant:

Zhang Xiao

Study leader:

Liu Jian gang

申请注册联系人电话:

Applicant telephone:

15610145335

研究负责人电话:

Study leader's telephone:

13651208096

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1107933820@qq.com

研究负责人电子邮件:

Study leader's E-mail:

liujiangang2002@sina.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

北京市海淀区中国中医科学院西苑医院

研究负责人通讯地址:

北京市海淀区中国中医科学院西苑医院

Applicant address:

Xi Yuan Hospital, China Academy of Chinese Medical Sciences, National Center for Clinical Cardiovascular Disease of Traditional Chinese Medicine, Beijing 100091

Study leader's address:

Xi Yuan Hospital, China Academy of Chinese Medical Sciences, National Center for Clinical Cardiovascular Disease of Traditional Chinese Medicine, Beijing 100091

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

北京市海淀区中国中医科学院西苑医院

Applicant's institution:

Xi Yuan Hospital, China Academy of Chinese Medical Sciences, National Center for Clinical Cardiovascular Disease of Traditional Chinese Medicine, Beijing 100091

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2023XLA112-2

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

中国中医科学院西苑医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee, Xi Yuan Hospital, China Academy of Chinese Medical Sciences

伦理委员会批准日期:

Date of approved by ethic committee:

2023/11/9 0:00:00

伦理委员会联系人:

訾明杰

Contact Name of the ethic committee:

Zi Mingjie

伦理委员会联系地址:

中国中医科学院西苑医院

Contact Address of the ethic committee:

Xi Yuan Hospital, China Academy of Chinese Medical Sciences

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 6283 5646

伦理委员会联系人邮箱:

Contact email of the ethic committee:

xiyuanlunli@163.com

研究实施负责(组长)单位:

中国中医科学院西苑医院

Primary sponsor:

Xi Yuan Hospital, China Academy of Chinese Medical Sciences

研究实施负责(组长)单位地址:

中国中医科学院西苑医院

Primary sponsor's address:

Xi Yuan Hospital, China Academy of Chinese Medical Sciences

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京市

市(区县):

海淀区

Country:

China

Province:

Bei Jing

City:

Hai Dian

单位(医院):

中国中医科学院西苑医院

具体地址:

中国中医科学院西苑医院

Institution
hospital:

Xi Yuan Hospital, China Academy of Chinese Medical Sciences

Address:

Xi Yuan Hospital, China Academy of Chinese Medical Sciences

经费或物资来源:

国家自然科学基金

Source(s) of funding:

National Natural Science Foundation of China (NSFC)

研究疾病:

心力衰竭

研究疾病代码:

Target disease:

Hearth failure

Target disease code:

研究类型:

Study type:

观察性研究

Observational study

研究设计:

Study design:

横断面

Cross-sectional

研究所处阶段:

Study phase:

其它

Others

研究目的:

整合分析射血分数保留型心衰患者蛋白组学和代谢组学的生物学特征,更好地阐明疾病的分子机制和发现临床标志物,探索中医证候本质。

Objectives of Study:

Integrating and analysing the biological features of proteomics and metabolomics of HFpEF patients to better elucidate the molecular mechanism of the disease and discover clinical markers, and to explore the nature of TCM evidence.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

符合HFpEF西医诊断标准;心功能(NYHA)分级标准为Ⅱ~Ⅳ级者;年龄45~95岁,性别不限;患者或家属同意,并签署知情同意书。

Inclusion criteria

Those who met the western medical diagnostic criteria for HFpEF; those who had a cardiac function (NYHA) classification standard of class II-IV; those who were 45-95 years old and of any gender; and those who gave consent from the patients or their families and signed the informed consent form.

排除标准:

由于先天性心脏病、瓣膜性心脏病、心肌炎、自身免疫性疾病等导致的心力衰竭;合并恶性肿瘤者;患者拒绝签署知情同意书,精神异常者;妊娠期或哺乳期妇女;近3个月参加其他研究者。

Exclusion criteria:

Heart failure due to congenital heart disease, valvular heart disease, myocarditis, autoimmune disease, etc.; those with co-morbid malignant tumours; patients who refused to sign the informed consent form, and those with mental abnormality; women in pregnancy or breastfeeding; and those who have participated in other studies in the last 3 months.

研究实施时间:

Study execute time:

From 2023-11-09

To      2024-11-09

征募观察对象时间:

Recruiting time:

From 2023-11-09

To      2024-11-09

干预措施:

Interventions:

组别:

对照组

样本量:

50

Group:

control group

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

组别:

HFpEF组

样本量:

150

Group:

HFpEF group

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

样本总量 Total sample size : 200

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

北京市

市(区县):

海淀区

Country:

China

Province:

Beijing

City:

Haidian

单位(医院):

中国中医科学院西苑医院

单位级别:

三甲中医院

Institution/hospital:

Xi Yuan Hospital, China Academy of Chinese Medical Sciences

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

蛋白组学

指标类型:

主要指标

Outcome:

proteomics

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

左心室射血分数

指标类型:

主要指标

Outcome:

LVEF

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

糖化血红蛋白

指标类型:

主要指标

Outcome:

HbA1c

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

E/e'

指标类型:

主要指标

Outcome:

E/e'

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

NT-pro BNP

指标类型:

主要指标

Outcome:

NT-pro BNP

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

代谢组学

指标类型:

主要指标

Outcome:

metabolomics

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心外膜脂肪厚度

指标类型:

主要指标

Outcome:

EAT

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 45
Min age years
最大 95
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

none

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

none

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统